Current advances in using neurotrophic factors to treat neurodegenerative disorders AM Weissmiller, C Wu Translational neurodegeneration 1 (1), 1-9, 2012 | 225 | 2012 |
Amyloid precursor protein–mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration W Xu, AM Weissmiller, JA White, F Fang, X Wang, Y Wu, ML Pearn, ... The Journal of clinical investigation 126 (5), 1815-1833, 2016 | 186 | 2016 |
Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance LR Thomas, CM Adams, J Wang, AM Weissmiller, J Creighton, SL Lorey, ... Proceedings of the National Academy of Sciences 116 (50), 25260-25268, 2019 | 105 | 2019 |
Displacement of WDR5 from chromatin by a WIN site inhibitor with picomolar affinity ER Aho, J Wang, RD Gogliotti, GC Howard, J Phan, P Acharya, ... Cell reports 26 (11), 2916-2928. e13, 2019 | 98 | 2019 |
Inhibition of MYC by the SMARCB1 tumor suppressor AM Weissmiller, J Wang, SL Lorey, GC Howard, E Martinez, Q Liu, ... Nature communications 10 (1), 1-12, 2019 | 84 | 2019 |
The MYC–WDR5 nexus and cancer LR Thomas, AM Foshage, AM Weissmiller, WP Tansey Cancer research 75 (19), 4012-4015, 2015 | 73 | 2015 |
MYC regulates ribosome biogenesis and mitochondrial gene expression programs through its interaction with host cell factor–1 TM Popay, J Wang, CM Adams, GC Howard, SG Codreanu, SD Sherrod, ... Elife 10, e60191, 2021 | 71 | 2021 |
Enhanced β-secretase processing alters APP axonal transport and leads to axonal defects EM Rodrigues, AM Weissmiller, LSB Goldstein Human molecular genetics 21 (21), 4587-4601, 2012 | 68 | 2012 |
WDR5 is a conserved regulator of protein synthesis gene expression AF Bryan, J Wang, GC Howard, AD Guarnaccia, CM Woodley, ER Aho, ... Nucleic acids research 48 (6), 2924-2941, 2020 | 57 | 2020 |
Impact of WIN site inhibitor on the WDR5 interactome AD Guarnaccia, KL Rose, J Wang, B Zhao, TM Popay, CE Wang, ... Cell reports 34 (3), 108636, 2021 | 51 | 2021 |
Interaction of MYC with host cell factor-1 is mediated by the evolutionarily conserved Myc box IV motif LR Thomas, AM Foshage, AM Weissmiller, TM Popay, BC Grieb, ... Oncogene 35 (27), 3613-3618, 2016 | 50 | 2016 |
Real-time imaging of axonal transport of quantum dot-labeled BDNF in primary neurons X Zhao, Y Zhou, AM Weissmiller, ML Pearn, WC Mobley, C Wu JoVE (Journal of Visualized Experiments), e51899, 2014 | 44 | 2014 |
A γ-secretase inhibitor, but not a γ-secretase modulator, induced defects in BDNF axonal trafficking and signaling: Evidence for a role for APP AM Weissmiller, O Natera-Naranjo, SM Reyna, ML Pearn, X Zhao, ... PloS one 10 (2), e0118379, 2015 | 39 | 2015 |
Targeting WDR5: A WINning anti-cancer strategy? ER Aho, AM Weissmiller, SW Fesik, WP Tansey Epigenetics insights 12, 2516865719865282, 2019 | 34 | 2019 |
Functional impact of corticotropin-releasing factor exposure on tau phosphorylation and axon transport MH Le, AM Weissmiller, L Monte, PH Lin, TC Hexom, O Natera, C Wu, ... PloS one 11 (1), e0147250, 2016 | 26 | 2016 |
Emerging Themes in Mechanisms of Tumorigenesis by SWI/SNF Subunit Mutation CA Jones, WP Tansey, AM Weissmiller Epigenetics Insights 15, 25168657221115656, 2022 | 22 | 2022 |
WIN site inhibition disrupts a subset of WDR5 function AJ Siladi, J Wang, AC Florian, LR Thomas, JH Creighton, BK Matlock, ... Scientific Reports 12 (1), 1-11, 2022 | 22 | 2022 |
Multiple interactions of the oncoprotein transcription factor MYC with the SWI/SNF chromatin remodeler CM Woodley, AS Romer, J Wang, AD Guarnaccia, DL Elion, JN Maxwell, ... Oncogene 40 (20), 3593-3609, 2021 | 17 | 2021 |
Increased cortical synaptic activation of TrkB and downstream signaling markers in a mouse model of Down Syndrome RL Nosheny, PV Belichenko, BL Busse, AM Weissmiller, V Dang, D Das, ... Neurobiology of disease 77, 173-190, 2015 | 17 | 2015 |
Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells AC Florian, CM Woodley, J Wang, BC Grieb, MJ Slota, K Guerrazzi, ... NAR Cancer 4 (1), zcac007, 2022 | 13 | 2022 |